samedan logo
 
 
spacer
home > pmps > winter 2002 > editor's letter
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Editor's Letter

The last 12 months have been something of a roller-coaster ride, with some big 'downs' and a few small 'ups'. Just now, we are in a tunnel waiting to find out what lies ahead. Overshadowing the economic climate post September 11th, there have been spectacular crashes like that of Enron Corp., largely due to voodoo accounting practices. Events such as these are a healthy reminder that leveraging earnings to achieve growth also increases risk. So far, the pharmaceutical industry has seemed immune from similar troubles, while the big merger of Pharmacia and Pfizer looks set to create the first mega-pharma company. M&A deals are pharma's attempt to regain shareholder value. However, the news is grim for employment prospects as the industry braces itself for yet more job losses in the wake of post-merger restructuring.


Earlier in the year, analysts predicted improved prospects for manufacturing which could have helped the production sector in pharma and biotech. Outsourced pharmaceutical manufacturing has proved remarkably resilient. It's as well that the industry has the support of a robust infrastructure enabling it to deliver quality products at costs that are lower than that of in-house manufacturing - as long as similar accounting standards are used to compare them. Is this golden scenario about to change to base metal, to match the leaden skies?


Read full article >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Patricia Lobo, Rebecca Cavalôt
spacer
Dr Patricia Lobo
spacer
spacer
spacer
Rebecca Cavalôt
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

4th Annual Patient Recruitment and Retention in Clinical Trials

13-15 October 2008, Amsterdam

Patient recruitment is now consuming thirty percent of clinical trial time - more time than any other clinical trial activity - and almost half of all trial delays result from patient recruitment problems. As the recruiting culture becomes more sophisticated and the forces affecting patient enrollment grow more numerous and complex, pharmaceutical companies are striving to discover new strategies to facilitate enrollment in clinical trials. With increasing industry pressure to develop, test and market greater numbers of new drugs faster, pharmaceutical companies need to perform clinical trials as quickly as possible. Inefficient patient recruitment processes is a formidable barrier to pharmaceutical companies' success in launching new products. Improving the patient recruitment process is imperative to avoid wasted investments and eliminate costly delays in bringing new drugs to market -- today and even more so in the not-so-distant future. Improved patient recruitment presents one of the largest opportunities for pharmaceutical companies to eliminate delays in clinical trials, thereby making it possible to reduce time to market.  With patent time limits and large overheads meaning that any delays in the development timeline can be disastrous, a good understanding of how to successfully recruit patients for trials is vital for any company looking to succeed.
More info >>

 
News and Press Releases

New PFA SonicLine® ultrasonic flowmeters

Flow measurement with ultrasound fast, precise, free from contamination         The new PFA SonicLine® ultrasonic flowmeters assure precise measurement and control of chemical consumption and management of chemical stocks with high reliability. SonicLine® is also ideally suited for accurate batch and dosing processes with high reproducibility.              
More info >>

 

©2000-2007 Samedan Ltd.
About Us | Register | Login | Site Map | Terms and Conditions | Contact Us |
Add to favourites

Print this page

Send to a friend
Privacy statement